Assessing the impact of metabolic dysfunction-associated steatotic liver disease on clinical outcomes in patients with acute myocardial infarction: a national inpatient sample analysis (2018–2020)

Anita Javanmardi; Umar Maqbool; Muhammad Ahmed Shaikh; Osama Ijaz; Sarah Musani; Zaland A Yousafzai; Amber Siddique; Noor Qanita Malik; Razeen Shafique; Seeme Rukh; Fatima Jawed; Faizan Ahmed; Hamza Bashir; Muhammad Adnan Kanpurwala; Ahmed Ali Aziz; Ashujot Kaur Dang; Muhammad Shikaib Shabbir

doi:10.1080/14796678.2026.2633969

February 20, 2026Future Cardiology

Assessing the impact of metabolic dysfunction-associated steatotic liver disease on clinical outcomes in patients with acute myocardial infarction: a national inpatient sample analysis (2018–2020)

View at Publisher

Ask AI

Bookmark

Share

Key result

MASLD in acute MI linked to higher mortality, longer stays, and increased healthcare costs.

Why the study?

Does the presence of MASLD worsen clinical outcomes in patients with acute myocardial infarction?

Key Points

To examine how metabolic dysfunction-associated steatotic liver disease affects clinical outcomes in acute myocardial infarction patients.
Analyzed data from a national inpatient sample between 2018 and 2020
Assessed mortality rates and hospital lengths of stay
Evaluated healthcare costs associated with AMI patients with MASLD.
AMI patients with MASLD had higher mortality rates compared to those without
Patients experienced longer hospital stays on average
Healthcare costs were significantly elevated for AMI patients with MASLD.

Structured PICO

Does the presence of MASLD worsen clinical outcomes in patients with acute myocardial infarction?

P

Population

Patients with acute myocardial infarction (AMI) from the National Inpatient Sample (2018–2020)

I

Intervention

Presence of metabolic dysfunction-associated steatotic liver disease (MASLD)

C

Comparator

Absence of MASLD

O

Outcome

Mortality rates, length of hospital stay, and healthcare costshard clinical

Implication

The presence of metabolic dysfunction-associated steatotic liver disease is associated with worse clinical and economic outcomes in patients hospitalized for acute myocardial infarction.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Javanmardi et al. (2026) studied this question. MASLD in patients with acute myocardial infarction is associated with higher mortality rates, longer hospital stays, and increased healthcare costs.

synapsesocial.com/papers/699beedd1c6c6bad5398026a https://doi.org/10.1080/14796678.2026.2633969

View at Publisher

Ask AI

Bookmark

Share

Assessing the impact of metabolic dysfunction-associated steatotic liver disease on clinical outcomes in patients with acute myocardial infarction: a national inpatient sample analysis (2018–2020)

Key Points

Structured PICO

Implication

Abstract

Discussion

Cite This Study

Assessing the impact of metabolic dysfunction-associated steatotic liver disease on clinical outcomes in patients with acute myocardial infarction: a national inpatient sample analysis (2018–2020)

Key Points

Structured PICO

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Future Cardiology

Keep reading

More related papers

More from Future Cardiology